Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies

Statistics

Original Article

Tofacitinib, un inhibidor oral de la quinasa Janus, para el tratamiento de artritis reumatoide en pacientes de Latinoamérica: eficacia y seguridad de estudios fase 3 y de extensión a largo plazo

Sebastião Cezar Radominskia, Mario Humberto Cardielb, Gustavo Citerac, Annelise Goecked, Juan Jose Jallere, Andrea Barranjard Vannucci Lomontef, Pedro Mirandag, Patricia Velezh, Daniel Xibilléi, Kenneth Kwokj, Ricardo Rojok,

Corresponding author

Ricardo.Rojo@pfizer.com

Corresponding author.

, Erika Gabriela Garcíal

a Universidade Federal do Paraná, Curitiba, Brazil

b Centro de Investigación Clínica de Morelia, Morelia, Mexico

c Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina

d Instituto de Ciencias Biomédicas, Hospital Clínico de la Universidad de Chile, Santiago, Chile

e University Metropolitana, Barranquilla, Colombia

f Hospital Heliópolis, São Paulo, Brazil

g Centro de Estudios Reumatológicos, Santiago, Chile

h CIREISAS, Bogotá, Colombia

i Hospital General de Cuernavaca, Cuernavaca, Mexico

j Pfizer Inc, New York, NY, USA

k Pfizer Inc, Groton, CT, USA

l Pfizer Inc, Collegeville, PA, USA

Read

8290

Times
was read the article

3013

Total PDF

5277

Total HTML

Share statistics

Article information

ISSN: 1699258X
Original language: English

DOI:10.1016/j.reuma.2016.04.010

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 May	21	9	30
2024 April	58	18	76
2024 March	46	42	88
2024 February	37	27	64
2024 January	23	27	50
2023 December	25	37	62
2023 November	41	32	73
2023 October	33	29	62
2023 September	134	35	169
2023 August	25	17	42
2023 July	28	30	58
2023 June	38	22	60
2023 May	36	29	65
2023 April	27	28	55
2023 March	84	33	117
2023 February	64	29	93
2023 January	38	30	68
2022 December	83	57	140
2022 November	62	45	107
2022 October	63	27	90
2022 September	31	33	64
2022 August	64	50	114
2022 July	67	49	116
2022 June	73	39	112
2022 May	43	36	79
2022 April	54	50	104
2022 March	56	45	101
2022 February	58	39	97
2022 January	50	40	90
2021 December	34	38	72
2021 November	43	41	84
2021 October	43	55	98
2021 September	38	44	82
2021 August	28	42	70
2021 July	17	22	39
2021 June	32	33	65
2021 May	36	41	77
2021 April	83	81	164
2021 March	57	47	104
2021 February	55	25	80
2021 January	56	20	76
2020 December	51	28	79
2020 November	45	25	70
2020 October	37	21	58
2020 September	52	38	90
2020 August	49	27	76
2020 July	45	18	63
2020 June	59	31	90
2020 May	110	24	134
2020 April	89	34	123
2020 March	96	30	126
2020 February	117	27	144
2020 January	96	49	145
2019 December	112	35	147
2019 November	105	10	115
2019 October	87	20	107
2019 September	50	37	87
2019 August	72	26	98
2019 July	54	18	72
2019 June	90	23	113
2019 May	77	41	118
2019 April	41	26	67
2019 March	62	31	93
2019 February	52	28	80
2019 January	39	26	65
2018 December	96	56	152
2018 November	158	17	175
2018 October	160	17	177
2018 September	74	6	80
2018 August	60	11	71
2018 July	22	6	28
2018 May	4	1	5
2018 April	68	12	80
2018 March	77	13	90
2018 February	64	9	73
2018 January	56	12	68
2017 December	46	10	56
2017 November	53	15	68
2017 October	58	23	81
2017 September	55	27	82
2017 August	122	34	156
2017 July	266	76	342
2017 June	27	34	61
2017 May	0	41	41
2017 April	0	27	27
2017 March	0	39	39
2017 February	0	21	21
2017 January	0	25	25
2016 December	0	30	30
2016 November	0	30	30
2016 October	0	72	72
2016 September	25	62	87
2016 August	68	59	127
2016 July	47	82	129

Show all

Indexed in:

Follow us:

Subscribe:

Statistics

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter